Destruction of tumor metabolism symbiosis is an attractive cancer treatment method which targets tumor cells with little harm to normal cells. Yet, a single intervention strategy and poor penetration of the drug in tumor tissue result in limited effect. Herein, we propose a zero‐waste zwitterion‐based hydrogen sulfide (H2S)‐driven nanomotor based on the basic principle of reaction in human body. When loaded with monocarboxylic acid transporter inhibitor α‐cyano‐4‐hydroxycinnamic acid (α‐CHCA), the nanomotor can move in tumor microenvironment and induce multiple acidosis of tumor cells and inhibit tumor growth through the synergistic effect of motion effect, driving force H2S and α‐CHCA. Given the good biosafety of the substrate and driving gas of this kind of nanomotor, as well as the limited variety of nanomotors currently available to move in the tumor microenvironment, this kind of nanomotor may provide a competitive candidate for the active drug delivery system of cancer treatment.

The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor sites accurately and properly activate complex immune responses. Herein, we design and prepare a kind of chemotactic nanomotor loaded with brain endothelial cell targeting agent angiopep-2 and anti-tumor drug (Lonidamine modified with mitochondrial targeting agent triphenylphosphine, TLND). Reactive oxygen species and inducible nitric oxide synthase (ROS/iNOS), which are specifically highly expressed in glioblastoma microenvironment, are used as chemoattractants to induce the chemotactic behavior of the nanomotors. We propose a precise targeting strategy of brain endothelial cells-tumor cells-mitochondria. Results verified that the released NO and TLND can regulate the immune circulation through multiple steps to enhance the effect of immunotherapy, including triggering the immunogenic cell death of tumor, inducing dendritic cells to mature, promoting cytotoxic T cells infiltration, and regulating tumor microenvironment. Moreover, this treatment strategy can form an effective immune memory effect to prevent tumor metastasis and recurrence.

No abstract

No abstract

A bright blue light excitable and narrow-band green-emitting phosphor Cs 3 MnBr 5 has been synthesized by a facile microwave radiation method within 2 min. The influence of the matrix on its steady-state and transient-state luminescence properties is investigated by partial substitution of Br − ions by Cl − ions. The incorporation of Cl − ions in Cs 3 Mn(Br 1−x Cl x ) 5 resulted in almost no change in the emission maxima of Mn 2+ , which is attributed to the synergistic effect of reduced covalency and increased crystal field strength caused by the replacement of Br − ions by Cl − ions. Meanwhile, the emission of Mn 2+ decreases with the increasing Cl − content, which is caused by different thermal quenching of Mn 2+ emission in the mixed Cl − /Br − coordination. Moreover, the incorporation of Cl − in Cs 3 Mn(Br 1−x Cl x ) 5 was found to have different effects on the lifetime of Mn 2+ at different temperatures, that is, at room temperature, the lifetime of Mn 2+ decreases with the increasing Cl − content, while at liquid nitrogen temperature, the lifetime of Mn 2+ increases upon increasing the Cl − content. The former is due to the different thermal quenching for different coordinations of Mn 2+ with Cl − and Br − , while the latter is due to the weaker spin− orbit coupling of the Mn 2+ ion caused by the interaction with the lighter Cl − ions, which makes the spin selection rule stricter and leads to a longer lifetime of Mn 2+ consequently.

Spinal cord injury (SCI) treatment requires a nanosystem for drug delivery that can effectively penetrate the blood–spinal cord barrier (BSCB). Herein, we designed poly­(2-methacryloyloxyethyl phosphorylgallylcholine) (PMPC)/l-arginine (PMPC/A)-based nanomotors that can release nitric oxide (NO). The nanomotors were loaded with the inducible NO synthase inhibitor 1400W and nerve growth factor (NGF). PMPC with a zwitterionic structure not only provided good biocompatibility for the nanomotors but also facilitated their passage through the BSCB owing to the assistance of a large number of choline transporters on the BSCB. Additionally, the l-arginine loaded on the nanomotors was able to react with reactive oxygen species in the microenvironment of the injured nerve to produce NO, thereby conferring the ability of autonomic movement to the nanomotors, which facilitated the uptake of drugs by cells in damaged areas and penetration in pathological tissues. Moreover, in vivo animal experiments indicated that the PMPC/A/1400W/NGF nanomotors could effectively pass through the BSCB and restore the motion function of a rat SCI model by regulating its internal environment as well as the release of therapeutic drugs. Thus, the drug delivery system based on nanomotor technology offers a promising strategy for treating central nervous system diseases.

Destruction of tumor metabolism symbiosis is an attractive cancer treatment method which targets tumor cells with little harm to normal cells. Yet, a single intervention strategy and poor penetration of the drug in tumor tissue result in limited effect. Herein, we propose a zero‐waste zwitterion‐based hydrogen sulfide (H2S)‐driven nanomotor based on the basic principle of reaction in human body. When loaded with monocarboxylic acid transporter inhibitor α‐cyano‐4‐hydroxycinnamic acid (α‐CHCA), the nanomotor can move in tumor microenvironment and induce multiple acidosis of tumor cells and inhibit tumor growth through the synergistic effect of motion effect, driving force H2S and α‐CHCA. Given the good biosafety of the substrate and driving gas of this kind of nanomotor, as well as the limited variety of nanomotors currently available to move in the tumor microenvironment, this kind of nanomotor may provide a competitive candidate for the active drug delivery system of cancer treatment.